Skip to main content
Evidence Snapshot

Vero

CHEMBL391 CELL-LINE Chlorocebus sabaeus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL391
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vero as ChEMBL target CHEMBL391. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vero
CELL-LINE · Chlorocebus sabaeus
As of 2026-09-14
ChEMBL target ID
CHEMBL391
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Vero matters

As of 2026-09-14

Vero is reviewed as Vero; the current evidence base includes 43 approved drugs, 20483 compounds, and 2758 assays, with lead potency reaching pChEMBL 10.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 43 approved drugs, 20483 compounds, and 2758 assays for this target. The dominant activity type is IC50. CHEMBL72086 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL72086 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
43 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Vero matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

20483
Total Compounds
2758
Total Assays
43
Approved Drugs
IC50: 9657.0, EC50: 494.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL72086
 10.2 IC50 —
No preferred name
CHEMBL323792
 10.2 IC50 —
No preferred name
CHEMBL78951
 9.8 IC50 —
No preferred name
CHEMBL1556
 9.6 IC50 Clinical
No preferred name
CHEMBL52609
 9.5 IC50 Clinical

Approved Drugs

Structure Compound First Approval
VORINOSTAT
CHEMBL98
 2006
MYCOPHENOLIC ACID
CHEMBL866
 2004
ADEFOVIR DIPIVOXIL
CHEMBL922
 2002
DOCETAXEL ANHYDROUS
CHEMBL92
 1995
TRIMETREXATE
CHEMBL119
 1993
PACLITAXEL
CHEMBL428647
 1992
PODOFILOX
CHEMBL61
 1990
ACYCLOVIR
CHEMBL184
 1982
DOXORUBICIN
CHEMBL53463
 1974
DACTINOMYCIN
CHEMBL1554
 1964
AMPHOTERICIN B
CHEMBL267345
 1964
FLUOROURACIL
CHEMBL185
 1962
COLCHICINE
CHEMBL107
 1961
NITROFURANTOIN
CHEMBL572
 1953
METHOTREXATE
CHEMBL34259
 1953
EMETINE
CHEMBL50588
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL391